Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.
January 2023 AbbVie Inc. Company Confidential
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.